Brief: Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold
Brief: Nasus Pharma Announces Closing Of $15.0 Million Private Placement
Brief: Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin As Executive Vice President And Chief Financial Officer
Brief: Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant Dosed
Brief: Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine Program